Raising the bar in bladder cancer care: Collaborative approaches to treatment selection, application and integration
The treatment landscape for advanced urothelial carcinoma (UC) and muscle-invasive bladder cancer (MIBC) is evolving rapidly, with emerging therapies creating new opportunities and new complexities in treatment selection, sequencing, and patient management.
Raising the Bar in Bladder Cancer Care brings together expert perspectives and practical, case-based learning to help clinicians navigate current and emerging treatment strategies, optimize multidisciplinary decision-making, and confidently integrate advances in bladder cancer care into clinical practice.
Start this program
Learning activities
Enrique Grande
María Teresa Bourlon
Michiel van der Heijden
Maria Lapuente
- Select and sequence guideline-recommended treatment for advance urothelial carcinoma based on patient factors, prior therapies and emerging evidence on optimal sequencing of treatments
- Evaluate clinical data supporting perioperative treatment strategies for MIBC, including for immunotherapy and antibody-drug conjugate (ADC) strategies
- Establish and apply patient-centred and multidisciplinary strategies to support treatment decision-making and adverse event management for newer treatment regimens in bladder cancer
In addition to the expert faculty, Springer Healthcare IME planners and staff include Kamran Ahmad and Rebecca Cox. The planning committee have no financial relationships to disclose.
All relevant financial relationships of the faculty have been mitigated.
Urologists, oncologists, surgeons, oncology nurses, physician assistants, pathologists and pharmacists involved in the care of patients with advanced UC and MIBC, and all other healthcare professionals (HCPs) managing bladder cancer.
